Johanna Claustre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johanna Claustre has a total of 472 co-authors. Here are the top co-authors by number of shared publications:
Antoine Roux
Hôpital Foch, Suresnes, France
7 shared publicationsMartine Reynaud-Gaubert
Aix Marseille Univ, APHM, INSERM, INRAE, C2VN, Hôpital Nord, Department of Respiratory Medicine, Marseille, France
7 shared publicationsAntoine Magnan
Institut du thorax, Inserm UMR 1087, CNRS, UMR 6291, Université de Nantes, Nantes, France
5 shared publications- Christophe Pison
Service Hospitalier Universitaire Pneumologie Physiologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble Cedex 9, France
5 shared publications Claire Dromer
CHU de Bordeaux, Bordeaux, France
5 shared publications- Pierre-Joseph Royer
Xenothera
5 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 258, 108885
Aspergillosis complicating idiopathic lung fibrosis: a multicentric series
- 14 May 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 258, 108885
Open AccessAspergillosis complicating idiopathic lung fibrosis: a multicentric series
- Open Access
Clinical evaluation of pharmacists’ interventions on multidisciplinary lung transplant outpatients’ management: results of a 7-year observational study
Objectives Lung transplant (LT) recipients require multidisciplinary care because of the complexity of therapeutic management. Pharmacists are able to detect drug-related problems and provide recommendations to physicians through pharmacists’ interventions (PIs). We aimed at assessing the clinical impact of PIs on therapeutic management in LT outpatients. Design Data were collected prospectively from an LT recipients cohort during 7 years. A multidisciplinary committee assessed retrospectively the clinical impact of accepted PIs. Setting French University Hospital. Participants LT outpatients followed from 2009 to 2015. Primary outcome measures Clinical impact of PIs performed by pharmacists using the CLEO tool and the Pareto chart. Results 1449 PIs led to a change in patient therapeutic management and were mainly related to wrong dosage (39.6%) and untreated indication (19.6%). The clinical impact of PIs was ‘avoids fatality’, ‘major’ and ‘moderate’, in 0.1%, 7.0% and 57.9%, respectively. Immunosuppressants, antimycotics for systemic use and antithrombotic agents had the greatest clinical impact according to the Pareto chart. PIs related to drug–drug interactions (10%) mainly had a moderate and major clinical impact (82.3%, pConclusion Clinical pharmacists play a key role for detecting drug-related problems mostly leading to a change in therapeutic management among LT outpatients. Our study provides a new insight to analyse the clinical impact of PIs in order to target PIs which have most value and contribute to patient care through interdisciplinary approach.
Open AccessClinical evaluation of pharmacists’ interventions on multidisciplinary lung transplant outpatients’ management: results of a 7-year observational study
Objectives Lung transplant (LT) recipients require multidisciplinary care because of the complexity of therapeutic management. Pharmacists are able to detect drug-related problems and provide recommendations to physicians through pharmacists’ interventions (PIs). We aimed at assessing the clinical impact of PIs on therapeutic management in LT outpatients. Design Data were collected prospectively from an LT recipients cohort during 7 years. A multidisciplinary committee assessed retrospectively the clinical impact of accepted PIs. Setting French University Hospital. Participants LT outpatients followed from 2009 to 2015. Primary outcome measures Clinical impact of PIs performed by pharmacists using the CLEO tool and the Pareto chart. Results 1449 PIs led to a change in patient therapeutic management and were mainly related to wrong dosage (39.6%) and untreated indication (19.6%). The clinical impact of PIs was ‘avoids fatality’, ‘major’ and ‘moderate’, in 0.1%, 7.0% and 57.9%, respectively. Immunosuppressants, antimycotics for systemic use and antithrombotic agents had the greatest clinical impact according to the Pareto chart. PIs related to drug–drug interactions (10%) mainly had a moderate and major clinical impact (82.3%, pConclusion Clinical pharmacists play a key role for detecting drug-related problems mostly leading to a change in therapeutic management among LT outpatients. Our study provides a new insight to analyse the clinical impact of PIs in order to target PIs which have most value and contribute to patient care through interdisciplinary approach.
- Open Access
- 8 June 2020
- Published by Elsevier in Annals of Intensive Care
- Vol. 10 (1) , 74-12
Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy
- 8 June 2020
- Published by Elsevier in Annals of Intensive Care
- Vol. 10 (1) , 74-12
Open AccessMucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy
- 21 November 2019
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 34 (3) , 408-411
Restrictive allograft dysfunction after lung transplantation: is there a place for nintedanib?—a case report
One of the post‐transplantation complications is represented by chronic lung allograft dysfunction, which has two main clinical presentations: bronchiolitis obliterans syndrome and restrictive allograft syndrome. The latter being challenging because of poor prognosis and only symptomatic treatment, and characterized by fibrotic process. A 63‐year‐old man was right lung transplanted in 2009 due to idiopathic pulmonary fibrosis. In 2011, bronchiolitis obliterans syndrome was diagnosed evolving to restrictive allograft syndrome in 2016. An off‐label treatment by nintedanib (150 mg twice a day) was introduced. Unfortunately, it was stopped four months later because of digestive intolerance, without any clinical improvement. Contrary to a previous case reported, our patient did not have any benefit of nintedanib. Antifibrotic agents’ effects such as nintedanib on restrictive allograft syndrom should be assessed in further randomized double blind placebo‐controlled studies.
- 21 November 2019
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 34 (3) , 408-411
Restrictive allograft dysfunction after lung transplantation: is there a place for nintedanib?—a case report
One of the post‐transplantation complications is represented by chronic lung allograft dysfunction, which has two main clinical presentations: bronchiolitis obliterans syndrome and restrictive allograft syndrome. The latter being challenging because of poor prognosis and only symptomatic treatment, and characterized by fibrotic process. A 63‐year‐old man was right lung transplanted in 2009 due to idiopathic pulmonary fibrosis. In 2011, bronchiolitis obliterans syndrome was diagnosed evolving to restrictive allograft syndrome in 2016. An off‐label treatment by nintedanib (150 mg twice a day) was introduced. Unfortunately, it was stopped four months later because of digestive intolerance, without any clinical improvement. Contrary to a previous case reported, our patient did not have any benefit of nintedanib. Antifibrotic agents’ effects such as nintedanib on restrictive allograft syndrom should be assessed in further randomized double blind placebo‐controlled studies.
- Open Access
- 15 July 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (11) , 3162-3175
Blood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation
- 15 July 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (11) , 3162-3175
Open AccessBlood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation
- 1 April 2019
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 36 (4) , 508-518
Sélection des candidats à la transplantation pulmonaire en France en 2019
- 1 April 2019
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 36 (4) , 508-518
Sélection des candidats à la transplantation pulmonaire en France en 2019
- 1 September 2018
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 35 (7) , 699-705
COLT : 10 ans de recherche en transplantation pulmonaire, résultats et perspectives
- 1 September 2018
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 35 (7) , 699-705
COLT : 10 ans de recherche en transplantation pulmonaire, résultats et perspectives
- 1 August 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (8) , 1382-1390
Donor Club Cell Secretory Protein G38A Polymorphism Is Associated With a Decreased Risk of Primary Graft Dysfunction in the French Cohort in Lung Transplantation
BackgroundClub Cell Secretory Protein (CCSP) G38A polymorphism has recently been involved in lung epithelial susceptibility to external injuries. Lung transplantation (LT) is currently limited by ischemia-reperfusion injury leading to primary graft dysfunction (PGD). We thus hypothesized that donor CCSP G38A polymorphism might impact the risk of PGD after LT. Methods We focused on LT included in the French multicentric Cohort in Lung Transplantation (COLT), performed between January 2009 and December 2014, and associated with preoperative blood samples from the donor and the recipient. Characteristics of the donors, recipients, procedures, early and late outcomes were prospectively recorded in COLT. The CCSP serum concentration and CCSP gene G38A polymorphism were retrospectively determined in a blind manner. Their association with grade 3 PGD was studied in univariate and multivariate analysis. Results The study group included 104 LT donors and recipients, 84 with grade 0 to 2 PGD and 20 with grade 3 PGD. Preoperative CCSP serum concentration was significantly higher in the donors (median, 22.54 ng/mL; interquartile range, 9.6-43.9) than in the recipients (median, 7.03 ng/mL; interquartile range, 0.89-19.2; P < 0.001) but none impacted the risk of grade 3 PGD (P = 0.93 and P = 0.69, respectively). Donor CCSP G38A polymorphism was associated with a decreased risk of grade 3 PGD in univariate (AG + AA 3/21 = 14.2% vs GG 10/26 = 38.4%, P = 0.044) and multivariate analysis (odds ratio associated with AG + AA, 0.22; 95% confidence interval, 0.041-0.88; P = 0.045), but recipient CCSP G38A polymorphism was not. Conclusions Donor CCSP G38A polymorphism is associated with a decreased risk of severe PGD after LT in the COLT study. These findings should be confirmed in the frame of a prospective study.
- 1 August 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (8) , 1382-1390
Donor Club Cell Secretory Protein G38A Polymorphism Is Associated With a Decreased Risk of Primary Graft Dysfunction in the French Cohort in Lung Transplantation
BackgroundClub Cell Secretory Protein (CCSP) G38A polymorphism has recently been involved in lung epithelial susceptibility to external injuries. Lung transplantation (LT) is currently limited by ischemia-reperfusion injury leading to primary graft dysfunction (PGD). We thus hypothesized that donor CCSP G38A polymorphism might impact the risk of PGD after LT. Methods We focused on LT included in the French multicentric Cohort in Lung Transplantation (COLT), performed between January 2009 and December 2014, and associated with preoperative blood samples from the donor and the recipient. Characteristics of the donors, recipients, procedures, early and late outcomes were prospectively recorded in COLT. The CCSP serum concentration and CCSP gene G38A polymorphism were retrospectively determined in a blind manner. Their association with grade 3 PGD was studied in univariate and multivariate analysis. Results The study group included 104 LT donors and recipients, 84 with grade 0 to 2 PGD and 20 with grade 3 PGD. Preoperative CCSP serum concentration was significantly higher in the donors (median, 22.54 ng/mL; interquartile range, 9.6-43.9) than in the recipients (median, 7.03 ng/mL; interquartile range, 0.89-19.2; P < 0.001) but none impacted the risk of grade 3 PGD (P = 0.93 and P = 0.69, respectively). Donor CCSP G38A polymorphism was associated with a decreased risk of grade 3 PGD in univariate (AG + AA 3/21 = 14.2% vs GG 10/26 = 38.4%, P = 0.044) and multivariate analysis (odds ratio associated with AG + AA, 0.22; 95% confidence interval, 0.041-0.88; P = 0.045), but recipient CCSP G38A polymorphism was not. Conclusions Donor CCSP G38A polymorphism is associated with a decreased risk of severe PGD after LT in the COLT study. These findings should be confirmed in the frame of a prospective study.
- 1 July 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (7) , 903-911
Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study
- 1 July 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (7) , 903-911
Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study